Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York September 04, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results August 14, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma August 14, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 August 06, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. July 01, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York May 30, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts May 15, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results May 13, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals to Present at Upcoming Investor Conferences May 09, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 May 08, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA March 26, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results February 29, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 February 22, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition February 05, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services January 29, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma January 05, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts January 04, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™ January 03, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan December 15, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London November 10, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results November 09, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 October 25, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 September 27, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference August 31, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises August 24, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum August 23, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting August 10, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results August 08, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Tickers VRCA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.